Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) EBITDA (2022 - 2025)

Historic EBITDA for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$9.0 million.

  • TriSalus Life Sciences' EBITDA fell 314.68% to -$9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.3 million, marking a year-over-year increase of 2703.06%. This contributed to the annual value of -$36.2 million for FY2024, which is 3361.17% up from last year.
  • Latest data reveals that TriSalus Life Sciences reported EBITDA of -$9.0 million as of Q3 2025, which was down 314.68% from -$7.3 million recorded in Q2 2025.
  • TriSalus Life Sciences' EBITDA's 5-year high stood at -$288273.0 during Q2 2022, with a 5-year trough of -$18.6 million in Q3 2023.
  • In the last 4 years, TriSalus Life Sciences' EBITDA had a median value of -$8.7 million in 2024 and averaged -$9.0 million.
  • Per our database at Business Quant, TriSalus Life Sciences' EBITDA plummeted by 386637.91% in 2023 and then soared by 5305.65% in 2024.
  • Over the past 4 years, TriSalus Life Sciences' EBITDA (Quarter) stood at -$11.8 million in 2022, then dropped by 21.03% to -$14.2 million in 2023, then soared by 46.8% to -$7.6 million in 2024, then dropped by 18.92% to -$9.0 million in 2025.
  • Its EBITDA stands at -$9.0 million for Q3 2025, versus -$7.3 million for Q2 2025 and -$7.3 million for Q1 2025.